PATENT CLAIM ANALYSIS

Application Number: 15891496
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "093210"]

Abstract:
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

Claim (Index 72):
The method of  claim 71 , wherein the CAR is an anti-CD19 CAR.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 88.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15045368', '14892934', '14051244', '15864984', '15120060']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.770796544047205
- 35 USC 102 Novelty (BERT): 0.5519094976895449
- Combined Prediction Score: 0.7489078394114389
- Mean Citation Score: 348.537274
- Max Citation Score: 435.2522
- Similarity Product: 302.2488098763466

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test